By Chris Wack

 

Pharvaris said Monday that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for deucrictibant for the on-demand treatment of hereditary angioedema following review of data from a preplanned interim analysis of the ongoing 26-week nonclinical study.

The company said it expects to submit data from the 26-week nonclinical study by the end of 2023 to address the remaining hold on the IND application for deucrictibant for prophylactic treatment of HAE.

"The lift of the clinical hold on our on-demand clinical trials enables us to continue development of PHVS416 deucrictibant immediate-release capsules in the U.S., including resuming RAPIDe-2, our extension study for acute treatment of attacks," said Peng Lu, chief medical officer of Pharvaris.

The company said it plans to request an end of Phase 2 meeting with the FDA and is preparing for its global Phase 3 study of PHVS416 for the on-demand treatment of HAE to include U.S. sites. Based on current enrollment, top-line data from its Phase 2 proof-of-concept study of PHVS416 for the prophylactic treatment of HAE remains on track to be announced by the end of the year.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

June 26, 2023 07:24 ET (11:24 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pharvaris NV Charts.
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pharvaris NV Charts.